Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Issue 1 (1st March 2015)

• Record Type: Journal Article
• Authors: Awasthi, Niranjan; Hinz, Stefan; Brekken, Rolf A.; Schwarz, Margaret A.; Schwarz, Roderich E.
• Is Part Of: Cancer letters. Volume 358:Issue 1(2015)
• Page Start: 59
• Page End: 66
• Publication Date: 2015-03-01
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2014.12.027
• Languages: English
• ISSNs: 0304-3835

Abstract

<abstract abstract-type="author-highlights" id="ab0010"> <title id="st0010">Highlights</title> <sec> <p id="sp0010"> <list id="ulist0010"> <list-item id="u0010"> <label></label> <p id="p0010">Nintedanib, a triple angiokinase inhibitor, was evaluated in pancreatic cancer.</p> </list-item> <list-item id="u0015"> <label></label> <p id="p0015">It inhibited <italic>in vitro</italic> proliferation of PDAC cells and blocked PI3K/MAPK activity.</p> </list-item> <list-item id="u0020"> <label></label> <p id="p0020">Nintedanib inhibited local tumor growth and enhanced gemcitabine response.</p> </list-item> <list-item id="u0025"> <label></label> <p id="p0025">Nintedanib therapy increased animal survival and enhanced gemcitabine response.</p> </list-item> <list-item id="u0030"> <label></label> <p id="p0030">Nintedanib-controlled mechanisms are potential targets for improved PDAC therapy.</p> </list-item> </list> </p> </sec> </abstract>